Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D3ID
|
||||
| Former ID |
DNC004037
|
||||
| Drug Name |
GAMMA-AMINO-BUTANOIC ACID
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528408] | ||
| Formula |
C4H9NO2
|
||||
| Canonical SMILES |
C(CC(=O)O)CN
|
||||
| InChI |
1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)
|
||||
| InChIKey |
BTCSSZJGUNDROE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid receptor subunit gamma-2 | Target Info | Inhibitor | [528408] | |
| Gamma-aminobutyric acid B receptor | Target Info | Inhibitor | [528071] | ||
| GABA transporter-3 | Target Info | Inhibitor | [533538] | ||
| Gamma-aminobutyric-acid receptor alpha-2 subunit | Target Info | Inhibitor | [533580] | ||
| Gamma-aminobutyric-acid receptor alpha-3 subunit | Target Info | Inhibitor | [533580] | ||
| Gamma-aminobutyric acid receptor | Target Info | Inhibitor | [528408] | ||
| Gamma-aminobutyric acid receptor subunit beta-2 | Target Info | Inhibitor | [528408] | ||
| Gamma-aminobutyric acid receptor subunit alpha-1 | Target Info | Inhibitor | [528408] | ||
| Gamma-aminobutyric-acid receptor alpha-5 subunit | Target Info | Inhibitor | [533580] | ||
| Sodium- and chloride-dependent GABA transporter 1 | Target Info | Inhibitor | [527271] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04024:cAMP signaling pathway | |||||
| Estrogen signaling pathway | |||||
| Morphine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| Nicotine addictionhsa04727:GABAergic synapse | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activationR-HSA-1296041:Activation of G protein gated Potassium channels | |||||
| G alpha (i) signalling events | |||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunitsR-HSA-975298:Ligand-gated ion channel transport | |||||
| GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport | |||||
| GABA A receptor activationR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters | |||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transportWP501:GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Potassium Channels | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transportWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transportWP706:SIDS Susceptibility Pathways | |||||
| Iron uptake and transportWP727:Monoamine Transport | |||||
| NRF2 pathway | |||||
| References | |||||
| Ref 527271 | J Med Chem. 2004 Nov 4;47(23):5620-9.Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. | ||||
| Ref 528071 | J Med Chem. 1991 Aug;34(8):2557-60.3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. | ||||
| Ref 528408 | J Med Chem. 2006 Sep 7;49(18):5571-7.3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. | ||||
| Ref 533538 | J Med Chem. 1981 Jul;24(7):788-94.Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. | ||||
| Ref 533580 | J Med Chem. 1980 Jun;23(6):702-4.New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.